Lung Cancer Screening Market Analysis 2025 to 2032

Posted 2026-02-04 10:16:28

Market Overview

The Lung Cancer Screening Market constitutes an essential segment of worldwide healthcare diagnostics which uses state-of-the-art imaging systems and diagnostic equipment to detect lung cancer early. Lung cancer maintains its position as one of the primary causes of cancer deaths worldwide yet early detection enables patients to receive better treatment which leads to better survival results. The market contains several screening methods including low-dose computed tomography (LDCT) as well as chest X-rays and biomarker-based blood tests and molecular diagnostics.

Key Players

Siemens Healthineers, GE Healthcare, Koninklijke Philips NV, Toshiba Medical Systems Corporation, Hitachi Medical Corporation, Hologic Inc, Esaote SpA, Canon Medical Systems Corporation, Mindray Medical International Limited, Siemens AG, Thermo Fisher Scientific Inc, Roche Diagnostics, Illumina Inc, Qiagen NV, BioRad Laboratories Inc, Sysmex Corporation, Abbott Laboratories, Becton Dickinson and Company, Cepheid, GenMark Diagnostics Inc

Sample link - https://www.trendbridgeinsights.com/industry-report/lung-cancer-screening-market

Market segmentation:

Screening Type

· Computed Tomography CT Scan

· Chest Xray

· Sputum Cytology

· Positron Emission Tomography PET Scan

· MRI

End User

· Hospitals

· Diagnostic Imaging Centers

· Cancer Research Institutes

· Ambulatory Surgical Centers

· Others

Age Group

· Below years

· years

· Above years

Risk Factors

· Smoking

· Exposure to Radon Gas

· Family History of Lung Cancer

· Occupational Exposure to Carcinogens

· Air Pollution

Mega Trend Connect:

This report offers deep insights into how mega trends such as value-based care, care decentralization, workforce optimization, and digital service integration are transforming healthcare services. It further examines the impact of integrated care models, service-line specialization, virtual service extension, and outcomes-based reimbursement. The report assesses regulatory oversight, labor constraints, cost inflation, and system capacity shaping service delivery models.

Global Trade Outlook:

Healthcare services trade is primarily constrained by licensing, accreditation, and jurisdiction-specific care regulations. Cross-border scalability is limited, pushing providers toward local operating models and partnerships. Competitive advantage depends on regulatory compliance, workforce availability, and localized service execution.

Region Analysis :

The lung cancer screening market is led by North America due to strong insurance coverage and advanced diagnostics. Europe grows through government programs, while Asia-Pacific expands rapidly. Latin America and Middle East and Africa show emerging adoption.

Recent development :

In March 2025,Siemens Healthineers introduced an AI-based imaging software which improves both diagnostic accuracy and operational efficiency during LDCT scan assessments of lung nodules.

FAQ:

1 . What is the projected market size & growth rate of the Lung Cancer Screening Market?

Lung Cancer Screening Market was valued at USD 2.1 billion in 2024 and is expected to reach to USD 5.7 billion by 2032, growing at a CAGR of 13.1% from 2025 to 2032.

2. What are the key driving factors for the growth of the Lung Cancer Screening Market?

Lung Cancer Screening Market is driven by Rising Incidence of Lung Cancer, Favorable Government Guidelines & Programs, Technological Advancements in Imaging & AI Diagnostics, High Cost of Screening & Infrastructure Requirements, Radiation Exposure Concerns, Limited Awareness & Low Screening Uptake Rates, Integration of Biomarkers & Liquid Biopsy Techniques, Expansion of AI and Digital Health Solutions, Government and NGO-led Awareness Campaigns, Inconsistent Screening Guidelines Across Regions, Overdiagnosis and False Positives, Workforce and Training Gaps.

3. What are the top players operating in the Lung Cancer Screening Market?

The major players in the market are Siemens Healthineers, GE Healthcare, Koninklijke Philips NV, Toshiba Medical Systems Corporation, Hitachi Medical Corporation, Hologic Inc, Esaote SpA, Canon Medical Systems Corporation, Mindray Medical International Limited, Siemens AG, Thermo Fisher Scientific Inc, Roche Diagnostics, Illumina Inc, Qiagen NV, BioRad Laboratories Inc, Sysmex Corporation, Abbott Laboratories, Becton Dickinson and Company, Cepheid, GenMark Diagnostics Inc

4. What segments are covered in the Lung Cancer Screening Market?

The Global Lung Cancer Screening Market is segmented based on Screening Type, End User, Age Group, Risk Factors, and Geography.

About US: